Search the database for deliberate release of GM medicinal products
Displaying 1 - 5 of 5
|EU record number
|Company / Sponsor
|Importation of doses of V920 for Emergency Use
|Merck Sharp & Dohme B.V.
|Recombinant Vesicular Stomatitis Virus (rVSV) in which the gene encoding for the VSV glycoprotein G has been deleted and replaced with the gene encoding the Zaire Ebola virus (ZEBOV) glycoprotein (GP).
|A phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or resistant B-NHL
|Miltenyi Biotech GmbH
|CD19 and CD20 chimeric antigen receptor
|Only notified under the "contained use" procedure. Dossier submitted on 24/04/2017.
|A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukaemia
|Institut de Recherches Internationales Servier
|chimeric antigen receptor and suicide-ligand (RQR8)
|Only notified under the "contained use" procedure. Dossier submitted on 26/03/1998.
|Pilot study of immunization with recombinant canarypox virus vCP1469A expressing the MAGE-1.A1 and MAGE-3.A1 cytolytic T lymphocytes epitopes in patients with malignant melanoma, non-small cell lung carcinoma, head-and-neck squamous cell carcinoma, esopha
|Pasteur Mérieux Connaught
|HLA-A1 restricted CTL epitope of MAGE-1 and MAGE-3 genes
|Only notified under the "contained use" procedure. Dossier submitted on 24/10/1996.
|Prospective, open-label, parallel-group, randomized, multicenter trial comparing the efficacy of surgery, radiation, and injection of murine cells producing herpes simplex thymidine kinase vector followed by intravenous ganciclovir against the efficacy of
|Genetic therapy, Inc., Sandoz Pharma, Ltd
|Thymidine Kinase (HSV-TK1), neomycin resistance (NeoR)